. Author manuscript; available in PMC: 2023 Mar 1.

Published in final edited form as: Biometrics. 2020 Dec 9;78(1):337–351. doi: 10.1111/biom.13406

TABLE 3.

The proportions of treated and estimated mean outcomes in a SPRINT-eligible cohort

	WTP	All patients assigned to intensive SBP control	All patients assigned to standard SBP control	AIPW-based CE-ITR (95% CI)
Proportion of treated	$50K	1	0	0.595 (0.368, 0.840)
Proportion of treated	$100K	1	0	0.691 (0.423, 0.930)
Mean NMB outcome	$50K	435751	432320	437909 (434379, 441535)
Mean NMB outcome	$100K	1056424	1042118	1058360 (1051240, 1066055)

Note. Our effectiveness measure is life-years and the follow-up length is 15 years. The rule of assigning all patients to intensive SBP control is the optimal rule from a conventional cost-effectiveness analysis based on the average treatment effect on NMB across the full study population. We conducted 10-fold cross-validation to avoid overfitting and computed the 95% CI using bootstrapping.